Medical outcomes after canal wall-down mastoidectomy, external ear canal reconstruction, tympanoplasty, and mastoid obliteration for extensive cholesteatoma
European Archives of Oto-Rhino-Laryngology · 2026
DOI: 10.1007/s00405-026-10042-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2026. Verfasst von Michal Luntz und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Israel Society for Auditory Research, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Mastoidectomy, Tympanoplasty, Cholesteatoma, Middle Ear, Mastoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technion - Israel Institute of Technology.
Abstract (Originalsprache)
Objective
To report medical outcomes and time-related recidivism after extensive cholesteatoma treated with canal wall-down (CWD) mastoidectomy, external ear canal (EEC) reconstruction, tympanoplasty, and S53P4 bioactive-glass mastoid obliteration.
Methods
Retrospective study of 127 ears with extensive cholesteatoma treated at a tertiary center. Patients were scheduled for annual otoscopic and non-echo-planar DW MRI follow-up for up to 4 years. For each postoperative year, only ears attending that visit and all previous yearly visits were analyzed. Main outcomes were: completely epithelialized, dry ear; tympanic membrane and/or posterior–superior EEC retraction; retraction pocket (RP) cholesteatoma; and residual cholesteatoma on MRI.
Results
Follow-up attendance declined from 100% (127/127) in year 1 to 67.2% (41/61) in year 4. A dry, epithelialized ear was achieved in 96.9% (123/127). Retraction developed in 33.9% (43/127), with probabilities of 13.4%, 26.4%, 28.9%, and 34.1% at 1, 2, 3, and 4 years, respectively. RP cholesteatoma occurred in 11.8% (15/127) and residual cholesteatoma on MRI in 7.0% (9/127); 23% of retracted ears progressed to RP cholesteatoma. Children ≤ 11 years had higher rates of retraction and RP cholesteatoma.
Conclusions
Despite counseling on the importance of follow-up, attendance declined over time. CWD mastoidectomy with EEC reconstruction, tympanoplasty, and S53P4 obliteration yielded high long-term dry ear rates in extensive and recurrent cholesteatoma, but complete eradication was not achieved. Younger and re-operated patients were at higher risk of retraction and RP cholesteatoma. Recidivism appeared years after the first surgery, supporting prolonged follow-up. Reporting annual outcome incidence in future studies would enhance understanding of extensive cholesteatoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Israel Society for Auditory Research, Tel Aviv, Israel.
- Department of Nutritional Sciences, School of Health Sciences, Ariel University, Ariel, Israel.
- Assuta Medical Centers, Tel Aviv, Israel.
- Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel. Ronibarzilay1@gmail.com.
- Department of Otolaryngology-Head and Neck Surgery, Rambam Health Care Campus, Haifa, Israel. Ronibarzilay1@gmail.com.
Förderung
- Technion - Israel Institute of Technology
Zitieren
APA
Luntz, M., Hod, K., & Barzilai, R. (2026). Medical outcomes after canal wall-down mastoidectomy, external ear canal reconstruction, tympanoplasty, and mastoid obliteration for extensive cholesteatoma. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10042-0
Vancouver
Luntz M, Hod K, Barzilai R. Medical outcomes after canal wall-down mastoidectomy, external ear canal reconstruction, tympanoplasty, and mastoid obliteration for extensive cholesteatoma. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10042-0
BibTeX
@article{Luntz2026,
author = {Luntz, Michal and Hod, Keren and Barzilai, Roni},
title = {Medical outcomes after canal wall-down mastoidectomy, external ear canal reconstruction, tympanoplasty, and mastoid obliteration for extensive cholesteatoma},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
doi = {10.1007/s00405-026-10042-0}
}
EUVIMED